Clinical high-yield

Canadian Screening Guidelines Cheat Sheet for the MCCQE

This page puts the Canadian screening recommendations the MCCQE draws on into one place: who to screen, with what test, how often, and who to leave alone. It also shows how screening questions are built, where provincial programs differ, and where a US-trained reflex gives the wrong answer.

14 min read · Reviewed November 2026 against official Canadian sources

How the MCCQE tests screening

Screening sits in the health promotion and illness prevention dimension of the MCC blueprint, and it shows up across every discipline: a 52-year-old at a periodic health visit, a 30-year-old who wants a PSA test because a friend had one, a pregnant patient at her first prenatal visit. The exam is not asking whether you know that screening exists. It is asking whether you can pick the right test, at the right age, at the right interval, for a person with no symptoms, and whether you can say no to a test that does more harm than good.

Most screening items fall into four patterns. First, the straight recall item: which test and interval is recommended for this asymptomatic person. Second, the boundary item: the patient is 49, 75 or 80, and the age cut-off decides the answer. Third, the trap item: the patient has a symptom or a strong family history, so the question is really about diagnosis or high-risk surveillance, not population screening. Fourth, the communication item: the patient asks for a test the guideline does not support, and the best answer is an informed discussion of benefits and harms rather than a flat refusal or an automatic order.

Keep one idea in front of you while you read any screening stem: screening is for people who feel well. The moment a stem gives you rectal bleeding, a breast lump, hemoptysis or weight loss, the screening guideline no longer applies and you are working up a symptom.

  • Asymptomatic, average risk: apply the national screening recommendation.
  • Symptomatic: investigate the symptom; screening intervals are irrelevant.
  • Higher than average risk (strong family history, genetic syndrome, prior disease): follow surveillance or specialist guidance, not the population schedule.
  • Patient request outside the guideline: shared decision-making with honest numbers on benefit and harm.

Who writes Canadian screening guidance in 2026

For more than a decade the main national source has been the Canadian Task Force on Preventive Health Care (CTFPHC), an independent panel supported by the Public Health Agency of Canada. Its guidelines are short, graded (strong or weak, later strong or conditional) and built around benefits and harms in primary care. Most Canadian teaching material, and most MCCQE-style screening questions, rest on these recommendations.

The Task Force went through an external expert review in 2024 and 2025. In June 2026 the federal government announced a new National Advisory Committee on Preventive Health Services to take over the work of developing national preventive guidelines. Until that committee publishes new recommendations, the Task Force guidelines remain the reference most Canadian clinicians and question writers use, so they are what this page summarises. Check the PHAC site before your exam for any new statement.

Two other layers matter. Specialty societies (Diabetes Canada, the Canadian Cardiovascular Society, Hypertension Canada) publish their own case-finding advice, which sometimes casts a wider net than the Task Force. And the provinces and territories run the actual screening programs: they decide who gets an invitation letter, whether you can self-refer for a mammogram and whether cervical screening uses a Pap test or an HPV test. If a stem names a province and its program, follow the program. If it does not, the national guideline is the safest answer.

  • National guidance: CTFPHC guidelines (current reference) and the new National Advisory Committee on Preventive Health Services (from June 2026).
  • Specialty society guidance: Diabetes Canada, CCS lipid guidelines, Hypertension Canada.
  • Delivery: provincial and territorial screening programs, which can differ in start age, test and recall interval.

Cancer screening: the five you must know cold

Breast cancer. The Task Force advice has been stable for ages 50 to 74: mammography every 2 to 3 years, framed as a personal choice made after an informed discussion. For women aged 40 to 49 the 2024 draft update suggested not screening systematically, but offering mammography every 2 to 3 years to those who want it once they understand the benefits and harms. That draft was archived and never finalised, but the practical message for the exam is the same: in the 40s, screening is an informed choice, not a default order. The Task Force suggests not screening from age 75, and does not suggest supplemental MRI or ultrasound for dense breasts alone.

Cervical cancer. The 2013 Task Force guideline (still the national one) says do not screen before age 25, then cytology every 3 years from 25 to 69. Screening may stop at 70 if the person has been adequately screened, defined as three successive negative Pap tests in the last 10 years. If not adequately screened, continue every 3 years until that is achieved. Several provinces have now moved to HPV primary testing, typically from 25 to 69 every 5 years, often with self-collection; see the provincial section below.

Colorectal cancer. For average-risk adults aged 50 to 74: a fecal test (FIT or guaiac FOBT) every 2 years, or flexible sigmoidoscopy every 10 years. The recommendation is strong for 60 to 74 and weak for 50 to 59. Do not screen from 75. The Task Force recommends against colonoscopy as the primary screening test, which surprises many US-trained candidates. Colonoscopy is the follow-up test after a positive FIT, and the surveillance test for people at high risk.

Lung cancer. Low-dose CT annually, for up to three consecutive years, in adults aged 55 to 74 with at least 30 pack-years who currently smoke or quit less than 15 years ago, and only in settings with expertise in early diagnosis and treatment. Everyone else: do not screen. Chest X-ray, with or without sputum cytology, should not be used. Know how to calculate pack-years: packs per day multiplied by years smoked.

Prostate cancer. The 2014 Task Force guideline recommends against PSA screening at every age: strong against under 55 and 70 and over, weak against 55 to 69. On the exam, a man of 60 who asks for a PSA is a shared decision-making question. The best answer explains the possible benefit and the real harms (false positives, biopsy complications, overdiagnosis and overtreatment) and respects an informed choice; it is not an automatic PSA order and not a refusal to discuss.

  • Breast: 50 to 74, mammography every 2 to 3 years; 40 to 49 by informed choice; not from 75.
  • Cervix: 25 to 69, cytology every 3 years (national guideline); stop at 70 if adequately screened.
  • Colorectal: 50 to 74, FIT or gFOBT every 2 years, or flexible sigmoidoscopy every 10 years; no screening colonoscopy for average risk.
  • Lung: 55 to 74, 30+ pack-years, smoking now or quit under 15 years ago, LDCT yearly up to 3 times.
  • Prostate: no PSA screening; discuss if the patient asks.

Non-cancer screening in adults

Hypertension. Measure blood pressure at all appropriate primary care visits in adults 18 and over, using current Canadian measurement technique, and apply Hypertension Canada criteria to confirm the diagnosis. There is no fixed interval. More frequent checks make sense with age, multiple vascular risk factors, and in people of South Asian, Indigenous or African ancestry. Office readings alone rarely make the diagnosis on the exam; expect the next step to be out-of-office measurement.

Type 2 diabetes. The Task Force uses a risk-first approach: estimate risk with a validated calculator (FINDRISC preferred, CANRISK acceptable), then screen with A1C every 3 to 5 years if high risk and every year if very high risk. Do not routinely screen adults at low to moderate risk. An A1C of 6.5% or more is diagnostic. Diabetes Canada casts a wider net, recommending routine testing from mid-life and earlier for people with risk factors, so a stem written from a diabetes-clinic angle may expect earlier testing. If unsure, follow the risk factors given in the stem.

Abdominal aortic aneurysm. One-time ultrasound for men aged 65 to 80. Do not screen men over 80. Do not screen women (strong recommendation). Note the contrast with US guidance, which ties AAA screening to smoking history in a narrower age band.

Fragility fractures. The 2023 guideline is a two-step, risk-first approach for community-dwelling females aged 65 and over who are not already on treatment: calculate the 10-year risk of major osteoporotic fracture with the Canadian FRAX tool without bone density, discuss the result, and order a DXA of the femoral neck only if the patient would consider medication. Do not screen females 40 to 64 or males 40 and over. Rescreening within 8 years does not appear useful.

Hepatitis C. The Task Force recommends against screening adults who are not at elevated risk. The real exam skill is spotting risk: current or past injection drug use, incarceration, immigration from a region where hepatitis C is common, receipt of blood products or transplants in Canada before 1992, hemodialysis, needle-stick injury, or health care received without universal precautions. Those people should be tested, which is case-finding, not population screening.

Chlamydia and gonorrhea. Offer opportunistic screening once a year to sexually active people under 30 at primary care visits, using a self-collected or clinician-collected sample. This does not apply to people presenting with possible STI symptoms or to high-risk groups, who follow national STI guidance.

Tobacco. The 2025 adult guideline is about action rather than a test: know every patient's smoking status, encourage quitting, and offer behavioural support (clinician advice, counselling, text-message programs, self-help) and medication (nicotine replacement, varenicline, bupropion, cytisine), ideally combined. E-cigarettes are not suggested for most people as a cessation tool.

  • BP: every appropriate visit, adults 18+.
  • Diabetes: risk calculator first; A1C every 3 to 5 years if high risk, yearly if very high risk.
  • AAA: men 65 to 80, one ultrasound; never women.
  • Fractures: females 65+, FRAX first, DXA only if treatment would be considered.
  • Hep C: test risk groups; no population screening.
  • Chlamydia and gonorrhea: sexually active under 30, yearly, opportunistic.

The 'do not screen' list

A large share of marks in this area come from knowing what Canadian guidance does not support. These recommendations are written for people with no symptoms and no clinical concern. Each one has an exception built in, and the exam likes to test that exception.

Depression in adults (2025 update): do not screen all adults 18 and over with a questionnaire and cut-off score; instead ask about well-being and stay alert for symptoms. Depression in pregnancy and postpartum (2022): regular enquiry about well-being rather than universal instrument-based screening. Cognitive impairment (reaffirmed 2024): do not use instrument-based screening in asymptomatic adults 65 and over. Thyroid dysfunction (2019): do not measure TSH in asymptomatic nonpregnant adults. Impaired vision (2018): do not screen community-dwelling adults 65 and over in primary care. Esophageal adenocarcinoma (2020): do not screen adults with chronic GERD for Barrett esophagus unless alarm features are present. Developmental delay (2016): do not use standardized screening tools in children aged 1 to 4 with no parent or clinician concern. Pelvic exam (2016): do not perform a routine screening pelvic exam in asymptomatic women. Prostate (2014): no PSA screening.

In every one of these, the exception is the clue. A daughter worried about her father's memory, a patient on lithium or amiodarone, GERD with dysphagia or weight loss, a parent concerned about speech: these are clinical concerns, and the right answer is assessment, not a lecture on screening harms.

  • Depression: ask and observe; no questionnaire screening of all adults.
  • Cognition: no screening tool in well adults 65+; assess if anyone is concerned.
  • Thyroid: no TSH in well adults; test if on lithium, amiodarone, prior thyroid disease or neck radiation.
  • Barrett esophagus: no screening for chronic GERD alone; scope for alarm features.

Do not screen, unless...

Ask insteadDepression in adultsNo questionnaire screening of all adults. Ask about well-being; assess anyone with symptoms or a past mental health history.
Concern = assessCognitive impairment, 65+No screening tool in well older adults. A family member's concern or functional decline means you assess.
Risk = testThyroid (TSH)No TSH in well nonpregnant adults. Test if on lithium or amiodarone, after thyroid surgery or neck radiation.
Red flagBarrett esophagus in GERDNo scope for chronic GERD alone. Dysphagia, weight loss, anemia, bleeding or vomiting call for endoscopy.
DiscussPSARecommended against at every age. If the patient asks, discuss benefits and harms and respect an informed choice.
Concern = assessDevelopmental delay, 1 to 4 yearsNo standardized tool when nobody is worried. Any parent or clinician concern leads to assessment.
Risk = testHepatitis CNo population screening. Test injection drug use, incarceration, endemic-region origin, pre-1992 blood products.
Age gateBone density in women under 65Do not screen females 40 to 64 or males. Women 65+: FRAX first, DXA only if medication would be considered.
Each 'no' has an exception the exam loves to test.

Pregnancy and childhood screening points

Asymptomatic bacteriuria. Screen pregnant people once in the first trimester with a urine culture (not a dipstick). This 2018 recommendation applies to those not already at increased risk; people with recurrent UTI or urinary tract anomalies follow obstetric guidance. Treat a positive culture even without symptoms, because untreated bacteriuria in pregnancy raises the risk of pyelonephritis.

Mood in pregnancy and after birth. As above, the Task Force prefers regular, open questions about well-being at prenatal and postpartum visits over a universal questionnaire with a cut-off. A candidate who asks how the patient is coping, sleeping and bonding, and acts on what is heard, scores better than one who simply hands out a form.

Children. Developmental screening with standardized tools is not recommended when nobody is worried, but developmental surveillance (asking about milestones and listening to parents) is part of every well-child visit. Any concern from a parent, a teacher or the clinician turns surveillance into assessment. For growth, vision, hearing and newborn metabolic screening, provincial programs and pediatric society guidance apply, and a stem will usually tell you what the program found.

When the population guideline does not apply

Each Task Force guideline states who it is for. The exam writers know this and build distractors around it. For colorectal cancer, the guideline excludes people with prior colorectal cancer or polyps, inflammatory bowel disease, symptoms of colorectal cancer, a first-degree relative with colorectal cancer, or a hereditary syndrome such as familial adenomatous polyposis or Lynch syndrome. These people need colonoscopy-based surveillance on a specialist schedule, not FIT every 2 years.

Breast cancer guidance is for average-risk women. A known BRCA mutation, prior chest radiation at a young age, or a strong family history moves the patient into high-risk programs (often with MRI) run by provincial programs and genetics services. Lung cancer screening does not apply to a person who already has symptoms or a known lung cancer. Hepatitis C and STI guidelines carve out higher-risk groups explicitly.

When a stem gives you a risk factor, ask yourself whether it moves the patient out of the average-risk group. If it does, the answer is earlier, more frequent or different testing, usually with a referral.

Provincial programs: where the answer can change

Canada has one set of national recommendations but many delivery systems. Two recent changes are worth knowing because they appear in teaching cases and in what IMGs see on clinical placements.

Breast screening in your 40s. Ontario lowered the starting age of its breast screening program to 40 on October 8, 2024, so people aged 40 to 49 can self-refer for a mammogram without a referral. Other provinces have their own rules. This does not contradict the national advice: both treat screening in the 40s as available to those who choose it after an informed discussion.

HPV primary cervical screening. A few provinces have switched from cytology to HPV testing as the primary cervical screening test, generally for people aged 25 to 69 once every 5 years, and some offer self-collected kits. Others are planning the change. If an MCCQE stem describes an HPV-based program, follow the interval it implies; if it simply asks about national guidance, the 2013 Task Force answer (cytology every 3 years from 25) is the reference.

Colorectal programs mail or provide FIT kits for people aged 50 to 74 in most provinces, matching the national guideline. A positive FIT in any province leads to colonoscopy, not a repeat FIT.

Canadian versus US screening: the contrasts that cost marks

Many IMGs prepare with US resources first. US Preventive Services Task Force recommendations differ from Canadian ones in several high-yield places, and a confident US answer will be marked wrong on the MCCQE. The pattern is consistent: Canadian guidance tends to start later, screen less often, and put more weight on harms and on informed choice.

Breast: US guidance moved to every-2-year mammography from 40; the Canadian answer is 50 to 74 every 2 to 3 years, with the 40s by informed choice. Colorectal: US guidance starts at 45 and lists colonoscopy every 10 years as a first-line option; the Canadian answer starts at 50 and recommends against colonoscopy as the primary screening test. Lung: US criteria use a wider age range and a lower pack-year threshold; the Canadian answer is 55 to 74, 30 pack-years, quit under 15 years, up to three annual scans. AAA: US guidance targets men who have ever smoked in a narrower age band; the Canadian answer is all men 65 to 80, once. Prostate: US guidance allows individual decisions from 55 to 69; Canadian guidance recommends against PSA screening at all ages, while still supporting an informed conversation when a patient asks.

The fix is simple: when you see a screening question, consciously switch to the Canadian table before you look at the options.

Canadian answer versus US reflex

Canadian guidance (MCCQE answer)

  • Breast: 50 to 74, every 2 to 3 years; 40s by informed choice
  • Colorectal: 50 to 74, FIT every 2 years or sigmoidoscopy every 10
  • No colonoscopy as the primary screening test at average risk
  • Lung: 55 to 74, 30 pack-years, quit under 15 years, 3 annual LDCT
  • AAA: all men 65 to 80, one ultrasound
  • PSA: recommended against at all ages

Common US-trained habit

  • Mammography every 2 years from 40 as a default
  • Start colorectal screening at 45
  • Colonoscopy every 10 years as a first-line screen
  • Wider age range and lower pack-year threshold, yearly scans
  • Screen men only if they have ever smoked
  • Offer PSA as an individual decision from 55
When a stem asks about screening, pick the left column.

How to read a screening stem in 20 seconds

Read the age and sex first, then scan for symptoms, then for risk factors, then for what the patient wants. That order maps directly onto the decision: age and sex tell you which guidelines are in play, symptoms take you out of screening altogether, risk factors move you to surveillance, and preferences decide the communication answer.

Watch the wording of the lead-in. 'Most appropriate screening test' wants the guideline answer. 'Most appropriate next step' after a positive screen wants the diagnostic test (colonoscopy after positive FIT, colposcopy after high-grade cytology or HPV-positive triage, diagnostic imaging and biopsy after an abnormal mammogram). 'Most appropriate response' to a request wants shared decision-making language.

Distractors often include a test that is reasonable in the US, a test that is right but at the wrong interval, a test meant for symptoms (CEA, CA-125, chest X-ray), and a test for a condition the Task Force does not screen for. Eliminate those four and the answer is usually obvious.

Screening stem decision path

  1. 1Age and sexWhich national recommendations apply at this age? Note boundaries such as 49, 74, 75 and 80.
  2. 2Any symptom?Bleeding, a lump, weight loss, dysphagia or cough mean diagnostic work-up. Screening rules no longer apply.
  3. 3Any high-risk feature?First-degree relative, genetic syndrome, IBD, prior cancer or polyps: surveillance or referral, not the population test.
  4. 4Apply the Canadian test and intervalUse the national recommendation unless the stem describes a provincial program that differs.
  5. 5Positive screen?Move to the diagnostic test: colonoscopy after FIT, colposcopy after abnormal cervical screen, workup imaging after mammogram.
  6. 6Patient wants something elseExplain benefits and harms in plain numbers, check understanding, and respect an informed choice.
Run this in order before you look at the options.

How the MCCQE frames it: three mini cases

Case 1. A 47-year-old woman with no family history asks whether she should start mammograms because her sister-in-law was diagnosed at 52. Her risk is average: a sister-in-law is not a blood relative. The best answer explains that screening in the 40s is a personal choice, outlines the chance of benefit against false positives, extra imaging and overdiagnosis, and offers mammography every 2 to 3 years if she wants it after that discussion. Ordering MRI, or telling her she is too young to be screened, are both wrong.

Case 2. A 62-year-old man who smoked one pack a day from age 18 to 50 asks about lung cancer screening. He has 32 pack-years, but he quit 12 years ago, so he is eligible: 55 to 74, at least 30 pack-years, quit under 15 years. The answer is referral for low-dose CT in a program with expertise, annually up to three times. A chest X-ray is a classic distractor. If he had quit 16 years ago, he would no longer meet the Canadian criteria.

Case 3. A 56-year-old woman's father had colon cancer at 58. She has no symptoms and asks for 'the stool test'. A first-degree relative with colorectal cancer excludes her from the average-risk guideline. The best answer is colonoscopy, not FIT every 2 years. The skill being tested is noticing the exclusion, not remembering an interval.

A one-week plan to lock this in

Screening facts are short and testable, so they reward spaced repetition more than long reading. Spend 20 to 30 minutes a day for a week, then revisit once a week until the exam.

  • Day 1: write the five cancer recommendations from memory, check against this page, repeat until perfect.
  • Day 2: non-cancer adult screening (BP, diabetes, AAA, fractures, hepatitis C, STI) with the exclusions.
  • Day 3: the 'do not screen' list, each with the exception that turns it into an assessment.
  • Day 4: pregnancy and child points, then the provincial differences.
  • Day 5: Canada versus US contrasts; say the Canadian answer aloud for each.
  • Day 6: 30 mixed screening MCQs in this question bank, timed; review every wrong option.
  • Day 7: practise two shared decision-making scripts (PSA request, breast screening in the 40s) out loud for the NAC as well.

Questions candidates ask

Are the Canadian Task Force guidelines still valid now that a new committee exists?

In June 2026 the federal government announced the National Advisory Committee on Preventive Health Services to take over national preventive guideline work. Until it publishes new recommendations, the Task Force guidelines are still the reference most Canadian teaching uses. Check the Public Health Agency of Canada site close to your exam date.

Does the MCCQE expect provincial screening rules or national guidelines?

Unless a stem describes a specific provincial program, answer with the national recommendation. If the stem tells you the province uses HPV testing or allows self-referral at 40, work within that program.

At what age does colorectal screening start in Canada?

For average-risk adults, the Task Force recommends screening from 50 to 74 with a fecal test every 2 years or flexible sigmoidoscopy every 10 years. People with a first-degree relative with colorectal cancer or other high-risk features need earlier, colonoscopy-based surveillance.

Is colonoscopy ever the right screening answer?

Not for average-risk people under the Task Force guideline, which recommends against colonoscopy as the primary screening test. It is the right answer after a positive FIT and for high-risk patients such as those with a strong family history, IBD or a hereditary syndrome.

What should I do if a patient asks for a PSA test?

Canadian guidance recommends against PSA screening, but the exam rewards shared decision-making. Explain the small possible benefit, the risk of false positives, biopsy complications and overtreatment, and respect the patient's informed decision.

Who qualifies for lung cancer screening in Canada?

Adults aged 55 to 74 with at least 30 pack-years who smoke now or quit less than 15 years ago. They should have low-dose CT once a year for up to three years in a centre with lung cancer expertise. Chest X-ray is not a screening test.

When should bone density testing be ordered?

The 2023 Task Force guideline starts with FRAX without bone density in females 65 and over. DXA is ordered only if the patient would consider medication after discussing that risk. Females 40 to 64 and males are not screened, though anyone with a fragility fracture needs assessment.

Is cervical screening every 3 or every 5 years?

The national 2013 guideline uses cytology every 3 years from 25 to 69. Provinces that have switched to HPV primary testing generally screen every 5 years. Follow the program described in the stem; without one, give the national answer.

How should I study screening for the NAC as well as the MCCQE?

Learn the numbers for the MCCQE, then practise saying them to a patient for the NAC. A counselling station on breast screening in the 40s or a PSA request tests how you explain benefits, harms and choice, not only whether you know the guideline.

Try the bank before you pay

Make a free account to open sample MCCQE questions and NAC stations with full explanations and marking sheets, and see where you stand.

Start freeSee plans